Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
Ciclopirox 8% nail lacquer (topical antifungal)
A topical antifungal nail lacquer for fungal nail infection. It clears the fungus in roughly a third of people and leaves a normal-looking nail in far fewer.
Prescription medication — not a dietary supplement
Ciclopirox is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Ciclopirox doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2000–2026 with a typical study size of 460 participants.
Based on 21 studies · 3 meta-analyses · 6 RCTs · 13,919 total participants
Study base
21 studies indexedBy outcome
Every outcome below: Too few graded studies.
Scored on efficacy confidence, not on how well studied it is, and those point in opposite directions here. The evidence base is strong: a 2020 Cochrane review, a network meta-analysis, and phase III trials running to hundreds of patients each. What that evidence shows is a modest drug. Mycological cure is reliably better than vehicle (RR 3.15, 95% CI 1.93-5.12, moderate-quality). Complete cure, the endpoint a patient actually cares about, is rated LOW quality by Cochrane with a confidence interval running from 1.72 to 50.14, and the most recent phase III found no significant difference in complete cure against vehicle at all. Held at Moderate rather than higher because the endpoint that matters is the weakest one.
2 trials ongoing or recruiting · 9 completed on ClinicalTrials.gov
3 of the completed trials have posted results
Registered trials show research momentum for Ciclopirox, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Ciclopirox 8% nail lacquer was the first topical antifungal the FDA approved for onychomycosis, the fungal infection that thickens, discolours and crumbles toenails. It is painted on daily for 48 weeks.
It belongs on a nail goal for one reason and it is worth stating plainly: a large share of nails that look weak, ridged or crumbling are infected rather than brittle, and no amount of biotin or collagen touches an infection. If that is what you have, this is the category of answer.
If your nails are genuinely brittle and splitting, with no fungal diagnosis, this is not your answer and a keratolytic humectant is a better place to start. The evidence base is unusually good for a topical and the results are unusually modest.
Mycological cure, meaning the laboratory can no longer find the fungus, runs around 34% against 10% on the vehicle in the pivotal US trials.
Complete cure, meaning that plus a nail that actually looks normal, is much rarer, and a 2023 phase III trial found no significant difference in complete cure between ciclopirox, its vehicle and an active comparator. Oral terbinafine outperforms every topical in network meta-analysis.
The practical problem is daily application for a year, which most people do not complete.
Ciclopirox is a hydroxypyridone, not an azole. It binds trivalent metal cations such as iron, which shuts down the metal-dependent enzymes a fungus needs for energy production and for degrading peroxides. Because the target is different from the azoles and allylamines, cross-resistance with terbinafine or itraconazole is not expected.
The nail plate is a poor route for any drug. The 8% lacquer forms a film that leaves ciclopirox against the nail as the solvent evaporates, with concentration building over repeated daily applications. Reformulation work has focused almost entirely on getting more drug through the plate, which is why water-soluble and hydroxypropyl-chitosan versions exist.
Consult a clinician before use. No adequate trials in pregnancy exist and onychomycosis treatment is not urgent, so deferring it is the usual course. How much reaches the body depends on the formulation, amount and the nails and skin treated; low exposure alone does not establish safety in pregnancy or breastfeeding.
A randomised vehicle-controlled trial in 40 children aged 2 to 16 with non-matrix onychomycosis reported 77% mycological cure at 32 weeks against 22% on vehicle, with weekly lacquer removal and trimming. Still a clinician's decision.
A 70-person randomised pilot found no reduction in foot ulceration over 12 months, so it is not a prophylactic against ulcers. It did leave significantly fewer people with clinically diagnosed hyperkeratosis or tinea pedis at study end, 52.9% against 77.8%.
The medicated lacquer has to sit against the nail plate to work. Nail polish over or under it is a delivery question rather than a drug interaction, and the trial regimen did not include cosmetic polish.
The available source did not grade how severe these reactions were. This does not mean they were mild.
The available source did not grade how severe these reactions were. This does not mean they were mild.
Ciclopirox has an evidence score of 5/10 — moderate evidence based on 21 indexed studies, including 2 meta-analyses. A topical antifungal nail lacquer for fungal nail infection. It clears the fungus in roughly a third of people and leaves a normal-looking nail in far fewer. Representative study: PMID 31978269.
The best time to take Ciclopirox is in the evening. It can be taken on an empty stomach. No time-of-day pharmacology.
Ciclopirox has a safety rating of "moderate". That is a category, not a measure of individual risk, and there are precautions worth knowing. Reported side effects include application-site reaction, redness or irritation of the surrounding skin, nail changes including altered colour or shape. How often they occur is not established for all of them. Use caution if any of these apply to you: Known hypersensitivity to ciclopirox or any lacquer excipient.
Urea
Too few graded studiesCosmetic compoundA humectant at low strength and a keratolytic at high strength — one of the oldest, safest topicals, and rarely proven better than a cheap plain moisturiser.
Clindamycin (topical)
Too few graded studiesPrescription drugA topical antibiotic for acne that is slow rather than weak, and works best paired with a retinoid or benzoyl peroxide. Combined with a retinoid it is the most effective topical option for moderate-to-severe acne.
Efinaconazole
Too few graded studiesPrescription drugThe most effective topical for fungal toenail infection, on high-quality evidence. About one person in six gets a completely clear nail.
Dapsone (topical)
Too few graded studiesPrescription drugA topical sulfone for inflammatory acne that works measurably better in women than in men, and is safe in G6PD deficiency despite the oral drug's reputation.
Explore: Best supplements for Skin, Hair & Beauty
Edited by Dr. Baher Al Hakim · Last updated November 2026 · evidence from 21 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.